公开(公告)号：US20160074373A1

公开(公告)日：2016-03-17

申请号：US14762980

申请日：2014-01-23

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  THE UNIVERSTIY OF CHICAGO

发明人： Chuan HE ,  Jing WANG ,  Hualiang JIANG ,  Cheng LUO ,  Hong LIU ,  Junyan LU

IPC分类号： A61K31/4365 ,  A61K31/4355 ,  A61K31/4375 ,  A61K31/444

CPC分类号： A61K31/4365 ,  A61K31/4355 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/444 ,  A61K31/4741 ,  A61K31/4743 ,  A61K45/06 ,  C07D491/048 ,  C07D491/147 ,  C07D495/04 ,  C07D495/14 ,  A61K2300/00

摘要： Compositions and methods concern organic molecules that bind to human Atox1 and CCS at the copper trafficking interface of these proteins. This binding suppresses copper trafficking, which leads to inhibition of cancer cell proliferation and tumor growth. In addition to serving as an effective treatment of cancer, these organic molecules inhibit cellular copper uptake and can be used as treatment of disorders of copper metabolism such as Wilson's disease, which is characterized by copper overload, as well as wound healing.

摘要翻译： 组合物和方法涉及在这些蛋白质的铜贩运界面处结合人Atox1和CCS的有机分子。 这种结合抑制铜贩运，这导致癌细胞增殖和肿瘤生长的抑制。 除了作为癌症的有效治疗之外，这些有机分子抑制细胞铜摄取，并且可以用作铜代谢紊乱的治疗，例如以铜超载为特征的威尔逊氏病以及伤口愈合。

公开(公告)号：US20200261459A1

公开(公告)日：2020-08-20

申请号：US16651510

申请日：2018-08-29

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  SUZHOU SUPLEAD LIFE SCIENCES CO., LTD.

发明人： Bing ZHOU ,  Cheng LUO ,  Yaxi YANG ,  Yuanyuan ZHANG ,  Daohai DU ,  Hualiang JIANG ,  Gang QIAO ,  Xinjun WANG

IPC分类号： A61K31/519 ,  C07D487/04

摘要： The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.

公开(公告)号：US20240033244A1

公开(公告)日：2024-02-01

申请号：US18004623

申请日：2021-07-08

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  HANGZHOU LEADING EDGE PHARMACEUTICAL LTD. ,  SHANGHAI KANGQIAN BIOTECHNOLOGY LIMITED

发明人： Cheng LUO ,  Meng XU ,  Shijie CHEN ,  Yilin LI ,  Yantao CHEN ,  Hualiang JIANG ,  Kaixian CHEN ,  Zhanpeng JIANG

IPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/395 ,  A61K31/216 ,  A61P35/00

CPC分类号： A61K31/343 ,  A61K35/15 ,  A61K39/3955 ,  A61K31/216 ,  A61P35/00

摘要： A YTH N6-Methyladenosine RNA Binding Protein 1 (YTHDF1) attenuating agent, with a compound, and when bound to YTHDF1, the compound binds to amino acid residues 372-392, 479-494 and 526-535 of SEQ ID NO: 1. A modified antigen presenting cell (mAPC), with the mAPC being treated with a YTHDF1 attenuating agent. A composition, with a YTHDF1 attenuating agent, a mAPC treated with the YTHDF1 attenuating agent, and optionally a pharmaceutically acceptable carrier. A method for attenuating an activity of YTHDF1, by administering an effective amount of a YTHDF1 attenuating agent. A method for determining whether or not a candidate agent is a YTHDF1 attenuating agent, by contacting the candidate agent with a YTHDF1 mutant. A method for treating a disease, disorder or condition associated with an expression of an antigen in a subject in need thereof.